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The effects of a series of caprolactam derivatives with central depressant, convulsant or muscle relaxant activity were investigated 
upon y-aminobutyric acid (GABA) receptor-ionophore binding to rat brain membranes u~ing [3H]GABA, [3H]muscimol and [35S]- 
tert.-butylbicyclophophorothionate ([35S]TBPS) as ligands, and GABA responses in mouse spinal cord neurones in dissociated cell 
culture. Some caprolactams produced a picrotoxin-like chloride-dependent partial inhibition of muscimol binding and were potent in- 
hibitors of TBPS binding. One compound that was further investigated (4,4,6,6-tetramethylhexahydro-2H-azepin-2-one), inhibited 
GABA responses and increased the frequency of paroxysmal depolarizations in cultured neurones. Other caprolactams enhanced 
muscimol binding and were relatively weak inhibitors of TBPS binding, and one (3,3-diallyl-6,6-dimethylhexahydro-2H-azepin-2,4- 
dione) was shown to enhance GABA responses and produced quiescence of activity in cultured neurones. There was a direct correla- 
tion between caprolactam effects on muscimol binding in the presence of chloride ions and their effects on TBPS binding suggesting a 
similar site of action for the caprolactams influencing the binding of these two ligands. For the two classes of caprolactams, with re- 
spect to inhibition or enhancement of muscimol binding, there appeared to be a relationship between in vitro effects and their convul- 
sant or depressant activity in mice. Caprolactams may be useful low molecular weight probes for the study of GABA receptor-iono- 
phore complexes. 
INTRODUCTION 
A large number  of sedative or convulsant drugs 
contain a substituted lactam system. Examples in- 
clude drugs with 5- (phenytoin, ethosuximide), 6- 
(barbiturates, glutarimides, primidone and methy- 
prylon) and 7-membered ring systems (various ben- 
zodiazepines). Caprolactam (hexahydro-2H-azepin- 
2-one), the simplest 7-membered ring lactam has 
convulsant activity in high doses 3. This activity was 
found to be increased by alkylation (especially meth- 
ylation) at various positions, in particular at carbons 
4 and 6 of the lactam ring2, 5. Some other caprolac- 
tams, however, such as those with large alkyl substi- 
tuents at carbon 7 have sedative activity in miceL 
There iselectrophysiological evidence to suggest 
that the convulsant caprolactams may be acting as ~- 
aminobutyric acid ( G A B A )  antagonists 7. Little, 
however, is known about the mode of  G A B A  antag- 
onism by these caprolactams. G A B A  antagonists 
may be grouped into two main classes: (1) those act- 
ing upon the G A B A  recognition site, such as bicucul- 
line; and (2) those blocking GABA-act iva ted  chlo- 
ride ion fluxes at G A B A  receptor coupled chloride 
channels, e.g. picrotoxin (reviewed in Johnston 
et al. 6) and tert.-butylbicyclophosphorothionate 
(TBPS) 19. Recently, incubation conditions have 
been identified whereby both bicuculline-like and 
picrotoxin-like agents may affect in vitro G A B A  
binding to brain membrane preparations 21. In the 
presence of  physiological concentrations of chloride 
ions and at room temperature or above, picrotoxin 
and related convulsants produced a potent but partial 
inhibition of G A B A  binding to rat brain membranes.  
In contrast, both agonists and antagonists at the 
G A B A  recognition site fully inhibited binding either 
in the presence or absence of chloride ions 4. Several 
groups have demonstrated a chloride-dependent en- 
hancement of G A B A  receptor binding by barbitu- 
ratesl,11A3,ts,21,22, 23. [35S]TBPS has been introduced 
Correspondence: G. A. R. Johnston, Department of Pharmacology, University of Sydney, N.S.W., 2006, Australia. 
0006-8993/85/$03.30 © 1985 Elsevier Science Publishers B.V. (Biomedical Division) 
226 
recently as a ligand with which to study specific sites 
coupled to GABA and chloride recognition sites 19. A 
wide variety of drugs likely to interact with GABA 
receptor-ionophore complexes have been shown to 
inhibit TBPS binding 19, whereas benzodiazepine 
agonists enhance TBPS binding20. 
In the present experiments, the effects of pento- 
barbitone, picrotoxinin and several caprolactam de- 
rivatives with convulsant, sedative or muscle relax- 
ant activity in mice, were examined upon the binding 
of radiolabelled GABA, muscimol and TBPS to rat 
brain membranes. The effects of two caprolactams 
were further examined upon spontaneous electrical 
activity and responses to iontophoretically applied 
GABA in mouse spinal cord neurones in dissociated 
cell culture. It is reported that various caprolactam 
derivatives can modulate GABA receptor binding 
and GABA responses in vitro, most probably at the 
level of GABA receptor-coupled chloride channels. 
MATERIALS AND METHODS 
Washed synaptosomal membranes were prepared 
from whole rat brains as previously describedlT, is. 
Briefly, whole brains of male Sprague-Dawley rats 
(10-12 weeks old) were homogenized in 0.32 M su- 
crose and a P2 synaptosomal-mitochondrial pellet 
formed by differential centrifugation. This pellet was 
lysed in distilled water, and washed 8 times in 50 mM 
Tris-citrate buffer pH 7.1 at 2 °C, and frozen 1-14 
days. On the day of assay, membranes were washed 4 
times in incubation buffer, 20 mM potassium phos- 
phate, pH 7.5 at 25 °C which contained 120 mM po- 
tassium chloride unless otherwise indicated. 
[3H]muscimol (9.3 Ci/mmol, New England Nuclear) 
or [3H]GABA (74.5 Ci/mmol, New England Nucle- 
ar) binding assays were performed using 5 nM radio- 
ligand incubated with washed synaptosomai mem- 
branes (ca. 0.5 mg protein) and the test drug in 1 ml 
volume. Incubations were at 25 °C for 15 min and 
terminated by rapid centrifugation at 10,000 glS. 
Non-saturable binding of muscimol was determined 
using 100/*M muscimoi, and for GABA, using 1 mM 
GABA. 
TBPS binding was studied as described by Supavi- 
lai and Karobath 20 using 2 nM [35S]TBPS (69 Ci/ 
mmol, New England Nuclear) with 200 mM sodium 
chloride in 50 mM Tris-citrate buffer, pH 7.5, at 
23 °C. Non-saturable binding was determined using 
100/~M picrotoxinin. 
For electrophysiological studies cell cultures were 
prepared from spinal cords with attached dorsal root 
ganglia from 12-14-day-old mouse embryos, as de- 
scribed earlier 14 and spinal cord neurones (7-8 
weeks in vitro) were penetrated on the modified 
stage of an inverted phase-contrast microscope, us- 
ing high resistance (25-40 Mr2) glass micropipettes 
filled with either 4 M potassium acetate (KAc) or 3 M 
potassium chloride (KC1). Cultures were bathed in a 
phosphate buffered saline (composition in raM: NaC1 
143.4, KCI 4.2, CaCI2 0.9, MgCI 2 1.0 and glucose 5.6 
in 9.5 mM sodium phosphate buffer at pH 
7.35-7.40). Using a conventional bridge circuit, si- 
multaneous current injection and membrane poten- 
tial measurement were made with a single recording 
micropipette; data were recorded on a 6-channel 
Gould polygraph. 
For determination of spontaeous neuronal activ- 
ity, spinal cord neurones (at 36 °C) were impaled us- 
ing KAc-filled electrodes and activity determined 
over a 3-min period. Normal spontaneous activity 
consisted of random firing of action potentials with 
an admixture of excitatory and inhibitory synaptic 
potentials9.15. Following determination of activity in 
6-11 'control' cells, drugs were added to the bathing 
medium and activity determined in a further 4-15 
cells. 
In iontophoresis experiments, 10 mM MgC12 was 
added to the bathing medium to suppress sponta- 
neous activity, and the culture temperature was de- 
creased slightly (to 33 °C) to prolong culture viabili- 
ty. GABA (0.5 M, pH 3.2) was applied iontophoreti- 
cally to spinal cord neurones using 400 ms rectangu- 
lar current pulses (+0.5 to +20 hA) at 4-s intervals. 
Drugs or vehicle (0.1% or less dimethyl sulfoxide) 
were applied by miniperfusion (0.2 psi, 30 s) from a 
pipette 15-100/~m from the cell soma. Medium con- 
taining vehicle only did not alter responses to 
GABA. GABA responses (KCI recordings) of 6-9 
mV amplitude were evoked following membrane hy- 
perpolarization to -80 to -90 mV and were used for 
assessment of drug actions. Data were accepted only 
if the amino acid responses returned to control levels 
within 5 min following removal of the drug-con- 
taining pipette from the vicinity of the cell under 
study. When KAc recording micropipettes were 
~ 200 
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Fig. 1. Enhancement of GABA and muscimol binding by pen- 
tobarbitone. Data shown are from paired experiments per- 
formed in quadruplicate on two separate membrane prepara- 
tions. Standard errors are omitted for clarity and did not ex- 
ceed 10% of control for GABA binding and 6% of control for 
muscimol binding. 
used,  appl ica t ion of  G A B A  p r o d u c e d  m e m b r a n e  hy- 
pe rpo la r i za t ion  and an increase  in m e m b r a n e  con-  
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ductance  12. U s e  of  KCl -con ta in ing  record ing  micro-  
p ipet tes  al lows ch lor ide  ions to en t e r  the  cell ,  chang-  
ing the  equ i l ib r ium po ten t ia l  for  ch lor ide  ions f rom 
about  - 6 5  m V  to - 2 0  m V ,  and G A B A  responses  be-  
c o m e  depolar iz ing .  
T h e  p e n t o b a r b i t o n e  sod ium used in the  b inding  ex- 
pe r imen t s  was ob ta ined  f rom A b b o t t s ,  Aus t ra l i a ,  
whi le  that  used in the  e lec t rophys io log ica l  exper i -  
men t s  was pu rchased  f rom Sigma,  U . S . A .  G A B A  
(Sigma or  C a l b i o c h e m ) ,  musc imol  (Sigma)  and pic- 
ro toxin  (Sigma)  were  ob t a ined  commerc ia l ly ,  whi le  
p ic ro toxin in  was p r e p a r e d  by Dr .  R.  D.  Al lan .  T h e  
syntheses  of  the  capro lac tams  used have  b e e n  pub-  
l ished elsewhere2,5,10. S o m e  of  the  cap ro lac tams  re-  
qu i red  d imethy l  sulfoxide vehic le  for  so lubi l iza t ion  
(up to 0 .1% in e lec t rophys io log ica l  assays);  in these  
cases pa i red  cont ro l  expe r imen t s  wi th  equa l  vehic le  
concen t ra t ions  were  always p e r f o r m e d .  
TABLE I 
Chemical structures and pharmacological properties of the caprolactams studied 
Cony, convulsant; Depr, depressant; Lmc, loss of muscle control; Lrr, loss of righting reflex; n.t., not tested. 
Capro- Substituents Unsaturation 
lactam 
C3 C4 C6 C7 
Pharmacological 
properties* 
A H H CH3,CH 3 H - 
B H CH 3 CH3,CH 3 H - 
C H c n  3 CH3,CH 3 H C3,C4 
D H CH3,CH 3 CH3,CH 3 H - 
E H CH3,CH 3 CH 3 H C6,C7 
F H CI CH3,CH 3 H C3,C4 
G H H H C3H 7 - 
H H H H C4H 9 - 
I H H H Cyclohexyl - 
J H H H p-Nitrobenzyl - 
K H CI-C6H4-NH- CH3,CH 3 H - 
L H CH 2 = CHCH20- CH3;CH 3 H C3,C4 
M H CH --- CCH20- CH3,CH 3 H C3,C4 
N 2(CH3CH2CH2- ) O= CH3,CH 3 H - 
O 2(CH 2 = CHCH2- ) O= CH3,CH 3 H - 
Caprolactam = hexahydro-2H-azepin-2-one 
Cony (1 mg/kg) a 
Cony (CDs0 6 mg/kg) a 
Conv (CDs0 7 mg/kg) a 
Conv (< 1 mg/kg) a 
Conv (CDs017 mg/kg) a 
Conv (4 mg/kg) d 
Conv (60 mg/kg) TM 
Weak depr b 
Depr (100 mg/kg) b,d 
Potent depr b 
Depr (60 mg/kg) b,u 
Lmc (40 mg/kg) c 
Lrr (50 mg/kg) d 
Cony (40 mg/kg) ¢ 
n.t. 
Cony (40 mg/kg) c 




* Doses shown are for intraperitoneal injections into mice, either threshold doses or CDs0 values if determined. 
a Hutchison et aiS; b Duong et al.2; c Mooney et al.l°; d Ward, unpublished. 
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RESULTS 
Under  the present assay conditions, pentobarbi-  
tone stimulated G A B A  and muscimol binding to rat 
membranes as previously observed tS. Pentobarbi-  
tone was a slightly more potent enhancer of musci- 
mol binding (ECs0 = 336 + 20 ~M) than of G A B A  
binding (ECs0 = 428 + 23/~M) and also produced 
greater maximal enhancement  of muscimol binding 
at high barbiturate concentrations (Fig. 1). In con- 
trast, picrotoxinin inhibited both G A B A  and musci- 
mol binding. At  1/~M, picrotoxinin inhibited musci- 
mol binding by 15.1% and G A B A  binding by 14.5%, 
however, at 100/~M picrotoxinin, muscimol binding 
was inhibited much more than G A B A  binding 
(48.4% compared with 25.7% inhibition). Because 
of the greater sensitivity of muscimol binding to mod- 
ulation by barbiturates and picrotoxin, muscimol was 
used as the radioligand for investigation of caprolac- 
tam effects at G A B A  receptor - ionophore  com- 
plexes. The structures of the caprolactams studied 
and their in vivo activities are shown in Table I. The 
C4 and C6 methyl-substituted caprolactams ( A - F )  
(Table II) inhibited muscimol binding in a concentra- 
t ion-dependent  fashion. Compound D was the most 
potent,  significantly inhibited binding at 10/xM. Max- 
imal inhibition by compounds A - D  and F was typic- 
ally 35%; compound E was a less potent inhibitor of 
muscimol binding (Table II). 
The C7 substituted caprolactams ( G - J )  (Table 
III) had differing effects upon muscimol binding. 
While the propyl caprolactam (G) weakly inhibited 
muscimol binding, the butyl derivative (H) caused 
little alteration of binding while compounds with 
larger C7 substituents (I, J) enhanced muscimol 
binding at 500/2M and above. The C4 amino substi- 
tuted caprolactam (K) (Table IV) inhibited musci- 
mol binding and the C4 allyl ether substituted capro- 
lactam (L) enhanced binding, although its triple 
bonded analogue (M) lacked activity. Both the C3 
substituted 4-oxo caprolactams (N) and (O) en- 
hanced muscimoi binding. 
The effects of chloride ions were studied upon 
G A B A  receptor modulat ion by picrotoxin, pento- 
TABLE II 
Inhibition of rnuscimol binding by convulsant C4 or C6 methyl-substituted caprolactams 
Data shown are means 4- S.E.M. of control muscimol binding, 8-12 determinations on 2 or 3 separate membrane preparations, n.t., 
not tested. 
Concentration Caprolactam 
(,uM) A B C D E F 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
10 n.t. 98.4 4- 3.5 n.t. 89.5 4- 1.16 n.t. 93.5 4- 0.5 a 
50 101.3 4- 4.5 89.2 4- 2.9 a 93.3 4- 1.3 a 80.1 4- 0.86 n.t. 79.6 _+ 1.66 
100 85.0 4- 0.96 80.4 _+ 2.9 h 86.7 4- 1.7 b 72.1 4- 1.16 95.6 4- 2.2 78.0 4- 1.0 b 
500 76.5 4- 0.5 b 73.7 4- 2.4 b 73.7 4- 0.9 b 65.3 4- 1.16 90.0 _+ 2.2 a 70.0 4- 0.66 
1000 68.9 4- 0.8 b 65.6 4- 5.5 b 66.3 4- 0.9 b 64.2 4- 1.46 88.7 4- 1.l 6 62.4 4- 0.86 
2000 67.1 4- 0.86 66.7 4- 2.0 b 63.9 _+ 1.46 69.9 4- 3.16 n.t. 66.8 4- 2.96 
a p < 0.02; b p < 0.001 from paired control incubations, Student's 2-tailed t-test. 
TABLE III 
Effects of C7 substituted caprolactams on muscimol binding 
Legend and footnotes as for Table II. 
Concentration Caprolactam 
(lxM) G H 1 J 
100 96.7 +_ 1 .l 97.5 4- 1.7 107.6 4- 2.8 103.2 4- 2.5 
500 91.2 4- 0.9 a 106.0 4- 1.3 123.9 4- 3,1 b 122.6 4- 2.86 
1000 85.9 4- 1.3 b 104.7 4- 1.0 136.2 4- 3.76 135.4 4- 7.6 ~ 
2000 83.1 4- 1.6 b n.t. 146.4 _+ 6.76 133.1 4- 10.32 
TABLE IV 
Effects of various C3 or C4 substituted C6 dimethyl-caprolactams on muscimol binding 
Legend and footnotes as for Table II. 
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Concentration Caprolactam 
(gM) g L M N 0 
100 94.7 + 2.4 101.5 + 1.6 105.9 + 2.0 100.6 + 3.5 105.0 + 0.6 
500 81.1 + 3.3 b 114.5 + 1.6 b 99.7 + 5.8 107.9 + 3.6 122.6 + 3.4 b 
1000 78.0 + 1A b 130.4 + 1.2 b 104.1 + 2.5 132.5 + 2.0 b 136.0 + 5.4 b 
2000 67.6 + 2.9 b 142.7 + 7.5 b 107.3 + 3.4 129.8 + 10.4 192.9 + 8.1 b 
TABLE V 
Effects of chloride ions upon the modulation of muscimol/GABA binding by picrotoxinin, pentobarbitone and caprolactams 
Drug concentrations shown are micromolar. 
lnhibitors Enhancers 
+ chloride -chloride + chloride - chloride 
Picrotoxinin Pentobarbitone* 
10 65.0 + 0.7 88.6 + 1.9 b 200 146.0 + 13.0 101.3 + 2.8 a 
50 51.6 + 0.9 82.5 + 7.6 a 400 167.9 + 1.8 115.8 + 5.7 b 
100 51.6 + 1.3 76.9 + 0.5 b 800 180.1 + 5.1 128.8 + 3.0 b 
Caprolactam (D) Caprolactam (J) 
100 72.1 + 1.1 89.1 + 0.2 b 500 122.6 + 2.8 101.9 + 2.2 b 
500 65.3 + 1.1 79.6 + 1.2 b 1000 135.4 + 7.6 107.8 + 1.5 b 
1000 64.2 + 1.4 77.8 + 1.9 b 2000 133.1 + 10.3 100.4 + 1.1 a 
a p < 0.02; b p < 0.001 from chloride containing media, Student's 2-tailed t-test. 
* Data for pentobarbitone are for GABA binding (from Skerritt et alAS). Other data are for muscimol binding. 
b a r b i t o n e  a n d  ce r t a i n  c a p r o l a c t a m s  ( T a b l e  V) .  Inh i -  
b i t i on  of  m u s c i m o l  b i n d i n g  by  p i c r o t o x i n i n  ( 1 0 - 1 0 0  
p M )  a n d  c a p r o l a c t a m  ( D )  ( 1 0 0 - 1 0 0 0 / ~ M )  was  la rge-  
ly, bu t  no t  to ta l ly ,  d e p e n d e n t  u p o n  t h e  p r e s e n c e  of  
ch lo r ide  ions .  A l t h o u g h  m o d e r a t e l y  h igh  c o n c e n t r a -  
t ions  of  b o t h  c o m p o u n d s  i n h i b i t e d  b i n d i n g  in t he  ab-  
sence  of  c h l o r i d e  ions ,  s ign i f i can t ly  m o r e  i n h i b i t i o n  
of  m u s c i m o l  b i n d i n g  o c c u r r e d  in t h e  p r e s e n c e  of  chlo-  A 
ride.  B 
A s  p r e v i o u s l y  d e m o n s t r a t e d  18 e n h a n c e m e n t  o f  C 
D 
G A B A  b i n d i n g  by  p e n t o b a r b i t o n e  was h igh ly  de-  E 
p e n d e n t  o n  c h l o r i d e  ions .  S imi l a r  r e su l t s  w e r e  s e e n  F 
wi th  t he  d e p r e s s a n t  c a p r o l a c t a m  (J)  w h i c h  e n h a n c e d  G 
H 
m u s c i m o l  b i n d i n g  w e a k l y  (a t  o n l y  o n e  c o n c e n t r a t i o n )  I 
in t he  a b s e n c e  of  c h l o r i d e  ions .  T h e  G A B A  a n t a g o -  J 
nist ,  b i cucu l l ine  m e t h o c h l o r i d e  ( B M C )  ful ly i nh ib -  K 
L 
i ted  m u s c i m o l  b i n d i n g  b o t h  in t he  p r e s e n c e  a n d  ab-  M 
sence  of  c h l o r i d e  ions .  B M C  was ,  h o w e v e r ,  a m o r e  N 
p o t e n t  i n h i b i t o r  in t he  p r e s e n c e  of  c h l o r i d e  ions  O 
(ch lo r ide  f ree ,  IC50 = 14.8 + 0 . 6 / ~ M ;  120 m M  chlo-  
r ide  ions ,  IC50 = 5 .2  + 0 . 4 / ~ M  d a t a  f r o m  two  p a i r e d  
e x p e r i m e n t s  p e r f o r m e d  in q u a d r u p l i c a t e  o n  s e p a r a t e  
TABLE VI 
Effects of caprolactams on [35S]TBPS binding 
Values are means + S.E. of quadruplicate determinations. 
Caprolactam (5001~M) % Control binding 
13 + 1'  
9 + 1 "  
8 + 1 "  
2 + 1 "  
33 + 1" 
3 + 1 "  
38+  1" 
73 + 3* 
67 + 2* 
85 + 2* 
46 + 2* 
9 4 + 3  
108 + 1 
86 + 2* 
106 + 4 
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Fig. 2. Inhibition of GABA and muscimol binding by picrotoxi- 
nin. Data shown are from 4 experiments performed in quadru- 
plicate on separate membrane preparations. Standard errors 
did not exceed the size of the symbols used. 
membrane preparations). 
Most of the caprolactams inhibited [35S]TBPS 
binding at 500#M as indicated in Table VI. None sig- 
nificantly enhanced [35S]TBPS binding under condi- 
tions where diazepam clearly enhanced such bind- 
ing 2c~. There was a direct correlation (correlation co- 
efficient 0.89, P < 0.0001) between caprolactam ef- 
fects at 500 gM on TBPS binding (Table VI) and on 
muscimol binding in the presence of chloride ions 
(Tables I - I I I ) .  The two most potent inhibitors of 
TBPS binding, caprolactams (D) and (F) had ICs~ ~ 
A. PB 20pM PRE ~ ~~-,~POST 
values of 5.7 + 0.5 gM and 17.2 + 1.3 gM,  respec- 
tively, and were thus significantly less potent than 
picrotoxinin, ICs0 0.22 + 0.02 I~M. 
The effects of compounds (D) (4,4,6,6-tetrameth- 
ylhexahydro-2H-azepin-2-one) and (O) (3,3-diallyl- 
6,6-dimethylhexahydro-2H-azepin-2,4-dione), the 
most potent inhibitor and enhancer of muscimol 
binding, respectively, were assessed upon the re- 
sponses of mouse spinal cord neurones in dissociated 
cell culture to iontophoretically applied G A B A ,  and 
their effects compared with those of picrotoxin and 
pentobarbitone. In 5 cells, compound (D) inhibited 
G A B A  responses by 41.8 + 4.3% (mean + S.E.M.) 
at 100~M and by 66.4 + 3.0% at 500/~M. Picrotoxin 
(100 I~M) abolished G A B A  responses completely in 
all 4 cells tested (Fig. 3). Caprolactarn (O) failed to 
alter G A B A  responses at i00 gM (response 102.8 _+ 
2.1% control, 4 cells) but at 1 mM enhanced G A B A  
responses in every cell tested (response 114.2 +_ 
1.5% control, 5 cells). Pentobarbitone (20 ttM) en- 
hanced G A B A  responses by 43.1 _+ 4.0% (6 cells). 
Caprolactam (D) produced spontaneous paroxys- 
mal depolarizing events or repeated bursts of firing, 
(grade 4 or 5 activity 9) in 60% (9 of 15) of cells stud- 
ied, while only 27% (3 of 11) of cells in control medi- 
um displayed such activity. Although none of the 
cells under control conditions were quiescent (i.e. 
lacking spontaneous action potentials), in the pres- 
ence of 1 mM caprolactam (O), 7 of 9 cells (78%) 
CAPRO 1 lmM 
! , , / \ 
B. PTX 100pM CAPRO 2 lOOpM ~"c 
/~' /i 
, ~ , ~ /  ~ 
Fig. 3. Effects of caprolactams, pentobarbitone and picrotoxin upon GABA responses of mouse spinal cord neurones in culture. A: 
pentobarbitone, PB (20#M) and caprolactam (O) (CAPRO 1) enhanced GABA responses (cell membrane potentials = -75 and -80 
mV). B: inhibition of GABA responses by picrotoxin, PTX (100 #M) and caprolactam (D) (CAPRO 2) in separate neurones (cell 
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D. PTX l O0,uM E.CAPRO 2 500pM 
Fig. 4. Effects of caprolactams, pentobarbitone and picrotoxin 
upon spontaneous neuronal activity. A: spontaneous activity 
pattern in a 'control' cell. B: pentobarbitone, PB (500pM), and 
(C) caprolactam (O) (CAPRO 1) (1 raM) produced neuronal 
quiescence in most cells. D: picrotoxin, PTX (1.00 ~M) and ca- 
prolactam (E) (CAPRO 2) (500 ~M). Membrane potentials of 
all cells were between -50 and -60 mV. 
were quiescent. In the presence of compound (O), 
intracellular injection of depolarizing current could 
still evoke repetitive firing of action potentials. Fur- 
ther, cell membrane potentials were not depolarized 
in the presence of either caprolactam. It is thus un- 
likely that the caprolactam effects arise simply from 
toxicity. Pentobarbitone (500 pM) produced quies- 
cence in all 6 cells studied, as earlier noted 15, while 
picrotoxin (100 pM) produced paroxysmal depolari- 
zing events in all 4 cells studied. 
DISCUSSION 
The finding that pentobarbitone enhancement and 
picrotoxinin inhibition of GABA receptor binding 
are more pronounced when muscimol rather than 
G A B A  is used as the radioligand may suggest that 
GABA and muscimol interact somewhat differently 
with G A B A  receptor-ionophore complexes. While 
chloride-dependent enhancement of GABA recep- 
tor binding has been demonstrated for a variety of la- 
belled GABA receptor ligands 12, full barbiturate- 
concentration response curves for [3H]GABA and 
[3H]muscimol binding have not previously been de-  
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scribed within the one study. It is possible, however, 
that the apparent greater maximal enhancement of 
muscimol binding compared with GABA binding is 
the result simply of differing fractional binding site 
occupancies by the two radioligands. However, since 
pentobarbitone increases the density rather than the 
affinity of high affinity muscimol or GABA binding 
under the experimental conditions usedlS, z2 this in- 
terpretation is unlikely. 
In independent studies Olsen and Snowman tl 
found that high concentrations of picrotoxin (30 pM) 
inhibited GABA binding by about 25% while oth- 
ers8, 22 found that similar picrotoxin or picrotoxinin 
concentrations inhibited muscimol binding by about 
50%. We have confirmed these results by performing 
paired experiments with picrotoxinin on GABA and 
muscimol binding in several membrane preparations 
formed on different occasions. Other evidence exists 
that muscimol and GABA do not label identical pop- 
ulations of sites in brain membranes. Muscimol labels 
only one subclass of binding sites while GABA labels 
two populations in washed synaptosomal mem- 
branes 16. Unlike pentobarbitone, diazepam was a 
more potent enhancer of GABA than of muscimol 
binding. Since pentobarbitone and picrotoxinin are 
thought to act on or near GABA receptor coupled 
chloride channels it may be possible that muscimol la- 
bels a subclass of GABA receptors closely associated 
with GABA-coupled chloride channels. 
The C4 and C6 methyl substituted caprolactams 
are potent convulsants (Table I) and like picrotox- 
inin inhibited muscimol binding potently, but only 
partially (Table II). That the inhibition was partial 
was confirmed by the observation that 2 mM of com- 
pounds (A-F)  did not inhibit binding any more than 
1 mM of each particular caprolactam. Compounds 
(D) and (F) are the most potent inhibitors of musci- 
mol binding, while compound (E), a relatively weak 
convulsant, was a relatively weak inhibitor. 
The good quantitative correlation between the ef- 
fects of the caprolactams on TBPS binding and on 
muscimol binding in the presence of chloride ions in- 
dicate that the caprolactams are influencing binding 
to GABA agonist recognition sites and to antagonist 
sites associated with chloride channels in a similar 
manner. The appreciably greater potency of the ca- 
prolactams against TBPS binding indicate a closer 
association of their direct site of action with the chlo- 
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ride channels than with the GABA agonist recogni- 
tion sites. Thus the influence of caprolactams on mus- 
cimol binding is relatively weak compared to that of 
direct acting GABA agonists and furthermore re- 
quires the presence of chloride ions. 
There is a reasonable qualitative correlation be- 
tween in vivo activity and the nature of muscimol 
binding modulation for the C7 substituted caprolac- 
tams. The convulsant propyl compound (G) inhibited 
binding, while the depressants (I and J) enhanced 
muscimol binding. Caprolactam (H), a weak depres- 
sant, was inactive at 1 mM. No enhancement of 
TBPS binding was observed at the single concentra- 
tion of caprolactam tested, but the caprolactams 
which enhanced muscimol binding were all relatively 
weak inhibitors of TBPS binding. 
The relationship between behavioural activity and 
binding was less obvious for the remaining com- 
pounds (K-O).  Caprolactam (K), a depressant, in- 
hibited binding, but with an amino substituent it is 
possible that it inhibits binding at the muscimol rec- 
ognition site. The other compounds had complex in 
vivo activities, for example compound (O) is a con- 
vulsant but produces muscle paralysis at similar 
doses. This compound however, markedly enhanced 
GABA binding. With the possible exception of (K) it 
is unlikely that the caprolactams act directly upon 
GABA receptor recognition sites. Like picrotoxin 
and pentobarbitone, the modulatory effects of the 
convulsant and the depressant caprolactam tested 
were largely chloride-dependent. The partial nature 
of inhibition was different from that of bicuculline 
methochloride (BMC) which fully inhibited musci- 
mol binding. BMC was more potent in the presence 
of chloride ions, as earlier noted 22, which may sug- 
gest that GABA agonists and antagonists interact 
with GABA recognition sites differently. 
The behaviour of the caprolactams in the electro- 
physiological assays corresponded to their behaviour 
in the binding assays. Compound (D), which showed 
picrotoxin-like inhibition of muscimol and TBPS 
binding, inhibited GABA responses on spinal cord 
neurones in culture and produced spontaneous par- 
oxysmal depolarizing events. In contrast, compound 
(O), which enhanced muscimol binding without in- 
fluencing TBPS binding, enhanced GABA responses 
and like pentobarbitone produced quiescence in spi- 
nal cord neurones. Unfortunately, due to vehicle 
sensitivity of the electrophysiological assays, the ef- 
fects of caprolactam with clear depressant activity in 
vivo (such as I or J) could not be investigated. Earlier 
studies using extracellular recording from the sub- 
stantia nigra in vivo had demonstrated GABA antag- 
onist activity for compounds (B) and (C), following 
intravenous injection 7 however the site of action of 
the caprolactams could not be determined in that 
study. The caprolactams appear to be relatively se- 
lective in that compounds (C), (G) and (K) (100/.tM) 
did not inhibit the uptake of GABA on L-glutamate 
by rat brain slices (Johnston, unpublished) although 
some caprolactams at high concentrations inhibit the 
binding of diazepam to brain membranes (Davies 
and Skerritt, unpublished). 
For the relatively simple C4 and C6 methyl substi- 
tuted and C7 alkyl substituted caprolactams (A-J) 
there appears to be a direct relationship between 
their behavioural effects (convulsant or depressant) 
and their effects upon muscimol binding (inhibition 
or enhancement). This is in contrast to barbiturate 
effects upon GABA binding. While a correlation be- 
tween relative anaesthetic potency and relative 
GABA binding enhancement exists for sedative bar- 
biturates ~8, both sedative and convulsant barbitu- 
rates enhance GABA bindingll, Js.25. The relatively 
simple caprolactam molecular structure may provide 
another useful too! for the investigation of GABA- 
coupled channels and their modulation. 
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